Ceeto Capital Group LLC increased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 3.2% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 16,200 shares of the biopharmaceutical company’s stock after acquiring an additional 500 shares during the quarter. Ceeto Capital Group LLC’s holdings in Gilead Sciences were worth $1,187,000 as of its most recent SEC filing.
Several other large investors have also recently modified their holdings of the company. Private Wealth Management Group LLC acquired a new position in Gilead Sciences during the 4th quarter valued at approximately $29,000. Palisade Asset Management LLC acquired a new position in Gilead Sciences during the 1st quarter valued at approximately $29,000. Sachetta LLC acquired a new position in Gilead Sciences during the 4th quarter valued at approximately $30,000. Rakuten Securities Inc. acquired a new stake in shares of Gilead Sciences in the fourth quarter worth $33,000. Finally, Gladius Capital Management LP acquired a new stake in shares of Gilead Sciences in the fourth quarter worth $34,000. Institutional investors own 83.67% of the company’s stock.
Gilead Sciences Price Performance
GILD traded up $0.50 during midday trading on Friday, hitting $77.01. 7,453,639 shares of the company traded hands, compared to its average volume of 6,033,727. The company has a current ratio of 1.08, a quick ratio of 0.94 and a debt-to-equity ratio of 1.31. The company has a market capitalization of $95.94 billion, a price-to-earnings ratio of 213.92, a PEG ratio of 3.28 and a beta of 0.18. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $87.86. The business has a 50 day simple moving average of $67.79 and a two-hundred day simple moving average of $70.98.
Analysts Set New Price Targets
A number of analysts have recently weighed in on GILD shares. UBS Group cut their price objective on shares of Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 17th. Oppenheimer reiterated an “outperform” rating and issued a $105.00 price objective on shares of Gilead Sciences in a research note on Friday, April 19th. Barclays cut their price objective on shares of Gilead Sciences from $80.00 to $76.00 and set an “equal weight” rating on the stock in a research note on Monday, April 29th. TD Cowen cut their price objective on shares of Gilead Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a research note on Friday, April 26th. Finally, Royal Bank of Canada reiterated a “sector perform” rating and issued a $74.00 price objective on shares of Gilead Sciences in a research note on Monday, July 1st. Twelve analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Gilead Sciences currently has an average rating of “Hold” and an average target price of $81.81.
Check Out Our Latest Research Report on Gilead Sciences
Insider Transactions at Gilead Sciences
In other news, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $68.63, for a total value of $137,260.00. Following the transaction, the insider now directly owns 96,380 shares of the company’s stock, valued at $6,614,559.40. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.16% of the company’s stock.
About Gilead Sciences
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Read More
- Five stocks we like better than Gilead Sciences
- Using the MarketBeat Stock Split Calculator
- Is Crypto Cool Again? What Stocks You Should Be Watching
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Why Call Options Volume for These 2 Stocks Spiked Together
- Stock Splits, Do They Really Impact Investors?
- MarketBeat Week in Review – 7/22 – 7/26
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD – Free Report).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.